Brought to you by 
Glenmark gets rights to sell a generic form of Astellas' Locoid Lipocream in the US
03 Aug 2011
Executive Summary
Astellas Pharma Inc. and its US marketing partner, specialty dermatology drug company Triax Pharmaceuticals LLC, have granted Glenmark Generics a royalty-bearing license to market a generic form of Locoid Lipocream (0.1% hydrocortisone butyrate). Glenmark, which has the right to sell its inflammation/dermatitis cortocosteroid in the US by the end of 2013, says it should be entitled to 180 days of exclusivity since it is the first generic firm to file an ANDA for the drug. Sales of Locoid Lipocream were $38mm for 2010. This is the second litigation settlement Glenmark has completed this month; Nycomed US Inc. also granted it a license to sell a generic form of atopic dermatitis therapy Cutivate.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glenmark gets rights to sell a generic form of Astellas' Locoid Lipocream in the US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice